Want the key stats in the sections on this page as a document? or looking for a stats report of the in-depth stats? Use the print function at the bottom of any Cancer Stats page Share this page > Print or your browser options to print or save.
Lung cancer statistics
New cases of lung cancer, 2014, UK
Deaths from lung cancer, 2014, UK
Survive lung cancer for 10 or more years, 2010-11, England and Wales
Preventable cases of lung cancer, UK
- There were around 46,400 new cases of lung cancer in the UK in 2014, that’s 130 cases diagnosed every day.
- Lung cancer is the third most common cancer in the UK (2014).
- Lung cancer accounts for 13% of all new cases in the UK (2014).
- In males in the UK, lung cancer is the second most common cancer, with around 24,800 cases diagnosed in 2014.
- In females in the UK, lung cancer is the second most common cancer, with around 21,600 cases diagnosed in 2014.
- More than 4 in 10 (44%) lung cancer cases in the UK each year are diagnosed in people aged 75 and over (2012-2014).
- Incidence rates for lung cancer in the UK are highest in people aged 85-89 (2012-2014).
- Since the early 1990s, lung cancer incidence rates have decreased by less than a tenth (7%) in the UK, though this includes an increase in females (28%) and a decrease in males (29%).
- Over the last decade, lung cancer incidence rates have increased by less than a tenth (4%) in the UK, however this includes a decrease (8%) for males and an increase (18%) for females.
- Around three-quarters of lung cancer cases are diagnosed at a late stage in England (2014), Scotland (2014-2015) and Northern Ireland (2010-2014).
- Incidence rates for lung cancer are projected to fall by 7% in the UK between 2014 and 2035, to 88 cases per 100,000 people by 2035.
- 1 in 13 men and 1 in 17 women will be diagnosed with lung cancer during their lifetime.
- Lung cancer in England is more common in people living in the most deprived areas.
- Lung cancer is more common in White people than in Black or Asian people.
- An estimated 57,200 people who had previously been diagnosed with lung cancer were alive in the UK at the end of 2010.
- In Europe, more than 410,000 new cases of lung cancer were estimated to have been diagnosed in 2012. The UK incidence rate is seventh lowest in Europe for males and seventh highest for females.
- Worldwide, nearly 1.83 million new cases of lung cancer were estimated to have been diagnosed in 2012, with incidence rates varying across the world.
- There were around 35,900 lung cancer deaths in the UK in 2014, that’s 98 deaths every day.
- Lung cancer is the most common cause of cancer death in the UK (2014).
- Lung cancer accounts for 22% of all cancer deaths in the UK (2014).
- In males in the UK, lung cancer is the most common cause of cancer death, with around 19,600 deaths in 2014.
- In females in the UK, lung cancer is the most common cause of cancer death, with around 16,300 deaths in 2014.
- Almost half (48%) of lung cancer deaths in the UK each year are in people aged 75 and over (2012-2014).
- Mortality rates for lung cancer in the UK are highest in people aged 85-89 (2012-2014).
- Since the early 1970s, lung cancer mortality rates have decreased by almost a quarter (23%) in the UK, though this includes a decrease (52%) in males and an increase (91%) in females.
- Over the last decade, lung cancer mortality rates have decreased by around a twentieth (6%) in the UK, though this includes a decrease (16%) in males and an increase (6%) in females.
- Mortality rates for lung cancer are projected to fall by 21% in the UK between 2014 and 2035, to 58 deaths per 100,000 people by 2035.
- Lung cancer deaths in England are more common in people living in the most deprived areas.
- In Europe, nearly 354,000 people were estimated to have died from lung cancer in 2012. The UK mortality rate is 11th lowest in Europe for males and fifth highest for females.
- Worldwide around 1.59 million people were estimated to have died from lung cancer in 2012, with mortality rates varying across the world.
- 5 in 100 (5%) of people diagnosed with lung cancer in England and Wales survive their disease for ten years or more (2010-11).
- A tenth (10%) of people diagnosed with lung cancer in England and Wales survive their disease for five years or more (2010-11).
- Around a third (32%) of people diagnosed with lung cancer in England and Wales survive their disease for one year or more (2010-11).
- Lung cancer survival is higher in women than men at one- and five-years but similar at ten-years.
- Lung cancer survival in England is higher for people diagnosed aged under 40 years old (2009-2013).
- Almost half of people in England diagnosed with lung cancer aged 15-39 survive their disease for five years or more, compared with more than 5 in 100 people diagnosed aged 80 and over (2009-2013).
- Lung cancer survival has not shown much improvement in the last 40 years in the UK.
- In the 1970s, less than 5 in 100 people diagnosed with lung cancer survived their disease beyond ten years, now it's 5 in 100.
- When diagnosed at its earliest stage, more than a third of people with lung cancer will survive their disease for five years or more, compared with around 5 in 100 of people when diagnosed at a later stage.
- Five-year relative survival for lung cancer in men is below the European average in England, Wales and Scotland but Northern Ireland is similar to the European average.
- Five-year relative survival for lung cancer in women is below the European average in England, Wales, Scotland and Northern Ireland.
- A person’s risk of developing cancer depends on many factors, including age, genetics, and exposure to risk factors (including some potentially avoidable lifestyle factors).
- 89% (91% in males and 87% in females) of lung cancer cases each year in the UK are linked to major lifestyle and other risk factors.
- Smoking is the main avoidable risk factor for lung cancer, linked to an estimated 86% of lung cancer cases in the UK.
- An estimated 89% of lung cancers in the UK are linked to lifestyle factors including smoking, certain occupational exposures (13%), and ionising radiation (5%).
- Environmental tobacco smoke, ionising radiation, air pollution, and diesel engine exhaust cause lung cancer.
- A diet high in fruit and vegetables may protect against lung cancer – insufficient fruit and vegetables intake is linked to an estimated 9% of lung cancer cases in the UK.
- 'Emergency presentation' is the most common route to diagnosing lung cancer.
- GP referral is the route with the highest proportion of cases diagnosed at an early stage, for lung cancer.
- ‘Two-week wait’ standards are met by all countries, ‘31-day wait’ is met by all but Northern Ireland, and ‘62-day wait’ is not met by any country for lung cancer.
- A tenth of lung cancer patients receive major surgical resection as part of their cancer treatment.
- Around 9 in 10 patients had a ‘very good’ or ‘excellent’ patient experience.
- 9 in 10 patients are given the name of their Clinical Nurse Specialist.
The latest statistics available for lung cancer in the UK are; incidence 2014, mortality 2014 and survival 2010-2011 (all ages combined) and 2009-2013 (by age).
European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.
Lifetime risk estimates were calculated using incidence, mortality, population and all-cause mortality data for 2012.
Survival statistics give an overall picture of survival and (unless otherwise stated) include all adults (15-99) diagnosed, at all ages,
Routes to diagnosis statistics were calculated from cases of cancer registered in England which were diagnosed in 2012-2013. Staging proportions only include patients with a known stage (cases with an unknown stage at diagnosis are not included in the denominator).
Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. Lung cancer is part of the group 'Lung cancer' for cancer waiting times data. Codes vary per country but broadly include: trachea, bronchus and lung, thymus, heart, mediastinum and pleura, other and ill-defined sites of the respiratory system, mesothelioma, secondary cancers of the mediastinum, pleura or other and unspecified respiratory organs.
Cancer surgical resection rates data is for patients diagnosed in England between 2006 and 2010.
Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.
Deprivation gradient statistics were calculated using incidence data for three time periods: 1996-2000, 2001-2005 and 2006-2010 and for mortality for two time periods: 2002-2006 and 2007-2011. The 1997-2001 mortality data were only used for the all cancers combined group as this time period includes the change in coding from ICD-9 to ICD-10. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.
You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:
Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.
When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or
We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.